Harmony Biosciences

Harmony Biosciences

Yahoo Finance • 15 days ago

Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?

Is HRMY a good stock to buy? We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on r/StockPickNews by EaseQuiet529. In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc.'s share... Full story

Yahoo Finance • 25 days ago

Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI

We just covered the 10 Best Stocks to Buy Right Now According to AI and Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) ranks 10th on this list. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical compan... Full story

Yahoo Finance • last month

Hedge Funds Followed the April Equity Rally by Increasing Exposure to Technology Leaders, Hazeltree Finds

Strong interest in Meta and Amazon.com contrasted with declining Nvidia positioning and continued bearish sentiment toward Tesla NEW YORK & LONDON, May 20, 2026--(BUSINESS WIRE)--Despite geopolitical turbulence and a mix of high volatilit... Full story

Yahoo Finance • last month

A beaten-down biotech just lost a meaningful backer — should you care?

Key Points Sold 237,103 shares; estimated trade size $7.77 million (based on average closing price from January to March 2026) Quarter-end position value decreased by $8.87 million, reflecting both sale and price changes Transaction equal... Full story

Yahoo Finance • 3 months ago

Humana and Thor Hit the Casualty List

This article first appeared on GuruFocus. Battered stocks with prospects to revive and thriveBy John DorfmanApril 6, 2026 The Setup Think of my Casualty List as a court of appeals for stocks that have been punished perhaps not entirely... Full story

Yahoo Finance • 4 months ago

Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the 20 Best Investments in 2026.Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments Harmony Biosciences Holdings, Inc. (N... Full story

Yahoo Finance • 4 months ago

Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades

[Red Arrow Moving Down Over Graph Paper Background] MicroStockHub * Harmony Biosciences (HRMY [https://seekingalpha.com/symbol/HRMY]) is down ~10% in Monday trading after analysts at Deutsche Bank and Truist cut their rating. * Both f... Full story

Yahoo Finance • 7 months ago

Harmony Biosciences To Present New Data From Phase 3 Trial Of EPX-100 In Dravet Syndrome Next Week

(RTTNews) - Harmony Biosciences Holdings Inc. (HRMY) is set to highlight new open-label extension data from its ongoing ARGUS trial at the American Epilepsy Society Annual Meeting on December 8, 2025. ARGUS is a phase 3 trial evaluating t... Full story

Yahoo Finance • 9 months ago

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). Fragile X syndrome is a rare genetic disorder that is th... Full story

Yahoo Finance • 9 months ago

Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company. Continue Reading View Comments... Full story

Yahoo Finance • 9 months ago

First Week of HRMY November 21st Options Trading

Investors in Harmony Biosciences Holdings Inc (Symbol: HRMY) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRMY options chain for... Full story

Yahoo Finance • 10 months ago

Validea Joel Greenblatt Strategy Daily Upgrade Report - 9/5/2025

The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields. HARMONY BIOSCIENCES H... Full story

Yahoo Finance • 10 months ago

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock

Investors looking for growth chances often meet the difficulty of balancing expansion possibility with fair prices, a method usually called Growth at a Reasonable Price (GARP). This method looks for companies showing solid growth paths, go... Full story

Yahoo Finance • 10 months ago

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity

Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has been identified through a systematic screening process designed to find stocks with good fundamental characteristics at appealing valuations. This... Full story

Yahoo Finance • 10 months ago

Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals

Investors looking for growth opportunities without paying too much often use the "Affordable Growth" strategy, which focuses on companies with strong growth potential and reasonable prices. This method combines the appeal of high-growth st... Full story

Yahoo Finance • 11 months ago

Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup

Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has become an interesting option for investors looking for growth stocks with positive technical setups. The selection method blends fundamental and te... Full story

Yahoo Finance • 11 months ago

Validea Joel Greenblatt Strategy Daily Upgrade Report - 8/7/2025

The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields. GRIFFON CORP (GFF) is... Full story

Yahoo Finance • 11 months ago

Earnings call transcript: Harmony Biosciences Q2 2025 beats EPS expectations

Harmony Biosciences Holdings (HRMY) reported its second-quarter 2025 earnings, showcasing a stronger-than-expected earnings per share (EPS) of $0.92, surpassing the forecast of $0.72 by 27.78%. The company’s revenue, however, fell slightly... Full story

Yahoo Finance • 11 months ago

Harmony Bio earnings beat by $0.20, revenue fell short of estimates

Investing.com - Harmony Bio (NASDAQ: HRMY) reported second quarter EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5M versus the consensus estimate of $204.59M. Guidance Harmony Bio... Full story

Yahoo Finance • 11 months ago

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential

Harmony Biosciences Holdings (NASDAQ:HRMY [https://www.chartmill.com/stock/quote/HRMY]) has been recognized through a "Decent Value" screening method, focusing on stocks with solid fundamental valuation metrics, good profitability, financi... Full story